+10%

est. 2Y upside i

HealthcareSeries A

ZBiotics makes genetically engineered probiotics.

Rank

#635

Sector

Consumer Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: High

ZBiotics presents a strong upside opportunity driven by its innovative genetically engineered probiotic technology and impressive 100% YoY growth to ~$12M ARR, coupled with profitability.

Last updated: March 10, 2026

Bull (35%)+300%

ZBiotics successfully expands its product lines beyond hangover mitigation into diverse use-case probiotics like 'Sugar-to-Fiber' and other gut health solutions, achieving strong market adoption and overcoming regulatory hurdles. Revenue could reach $42M+ by 2028, justifying a $320M+ valuation at a premium multiple due to its proprietary genetically engineered technology and market leadership.

Base (40%)+50%

ZBiotics maintains its strong growth trajectory for its flagship pre-alcohol probiotic and sees moderate success with new product introductions. The company continues to be profitable, growing revenue to ~$36M by 2028 and achieving a $120M valuation, reflecting solid execution in a competitive consumer biotech market.

Bear (25%)-75%

ZBiotics faces significant regulatory setbacks for its genetically engineered products, or public health concerns lead to a decline in demand for hangover-mitigation products. Increased competition from traditional supplement companies or a large incumbent entering the space erodes market share, causing growth to slow. This could lead to a down round or an exit at a valuation of $20M or less, severely impacting common stock value given the substantial liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors have $40M in liquidation preferences. In an exit at or below $80M, common stock holders would see their returns significantly reduced or wiped out after investors are paid back their initial $40M.

Dilution Risk

high

As a Series A company, ZBiotics will likely require additional funding rounds, which will lead to further dilution of existing equity holders.

Secondary Liquidity

limited

While secondary marketplaces like Hiive and Nasdaq Private Market may offer limited opportunities, active secondary liquidity is not guaranteed for a company at this stage.

View all 3 open roles at ZBiotics →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on ZBiotics's data — designed to show you've done your homework.

  • 1

    “How is ZBiotics navigating the complex regulatory landscape for genetically engineered probiotics, particularly concerning GRAS and FDA approvals, and what is the timeline for expanding into new regulated markets?”

  • 2

    “With the success of the pre-alcohol probiotic, what are the key strategic priorities and resource allocations for scaling the 'Sugar-to-Fiber' product and other future use-case probiotics to ensure diversified revenue growth?”

  • 3

    “Given the Series A funding and the company's current valuation, how does ZBiotics envision the path to a liquidity event within the next 2-4 years, and what measures are in place to manage potential employee dilution in subsequent funding rounds?”

Community

Valuation Sentiment

Our model estimates +10% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.